The interview reflects a French academic-center perspective in which chemoradiotherapy remains the cornerstone of curative treatment for locally advanced cervical cancer, with immunotherapy increasingly layered into high-risk disease. In metastatic settings, platinum-based chemotherapy combined with PD-1 inhibition forms the dominant first-line approach, while options beyond first line remain limited, leading to strong reliance on clinical trials. Overall, the discussion highlights persistent unmet need post-IO, cautious reimbursement-driven adoption, and growing interest in ADCs as the most credible avenue for future progress.

This interview was conducted on 18 November 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.